AOD-9604 Research Guide: GH Fragment, Lipolysis Mechanisms, and Metabolic Research

By Sam Smith

The central challenge with full-length growth hormone as an obesity treatment has always been the off-target effects: insulin resistance, IGF-1-driven proliferative risk, acromegalic changes with long-term use. AOD-9604 was designed specifically to avoid all of that. Identified at the Howard Florey Institute in Melbourne in the 1990s by researchers who were systematically mapping which region of the HGH molecule drove fat metabolism, the 16-amino-acid C-terminal fragment (residues 177-191) was found to stimulate lipolysis and inhibit lipogenesis in adipocytes without binding the full hGH receptor and without raising IGF-1. That's a pharmacologically clean separation — one that looked promising enough that Metabolic Pharmaceuticals pursued it through Phase 3 obesity trials.

The clinical history is instructive. AOD-9604 reached Phase 3 human trials for obesity but failed to demonstrate statistically significant weight loss in the broader population — a result that redirected the compound toward research applications rather than pharmaceutical approval. Worth noting: the rodent data was genuinely compelling. Studies in obese ob/ob mice and diet-induced obese models showed measurable reductions in body fat percentage, and the mechanism — engaging a beta-adrenergic-like pathway in adipocytes that's distinct from the full HGH receptor — has been reproduced in multiple cell-culture systems. The gap between robust rodent results and modest human outcomes is one of the more common patterns in metabolic peptide research, and AOD-9604 is a clean case study in why translational assumptions need to be tested rather than assumed.

This guide covers how AOD-9604 drives lipolysis without HGH receptor binding, what the preclinical and clinical literature shows on weight loss and metabolic effects, how it compares with other fat-loss peptide approaches, dosing and administration in research protocols, and what researchers should look for when sourcing material.

What is AOD-9604 and how does it work?

AOD-9604 is a synthetic version of the lipolytic domain of human growth hormone. According to the original PubMed-indexed pharmacology paper, A synthetic analogue (AOD9604) of the lipolytic domain of human growth hormone (residues 177-191) was designed to isolate the fat-specific effects of HGH from its broader growth-promoting actions. The peptide fragment contains a disulfide bond and a free N-terminal tyrosine that together produce the lipolytic-specific activity.

The receptor mechanism is distinctive. Published research shows that AOD9604 does not compete for the hGH receptor and nor does it induce cell proliferation, distinguishing it from full-length HGH and from IGF-1-based interventions. The peptide acts through a still-undefined receptor or through direct interaction with adipocyte cell-membrane components, driving lipolysis without the broad anabolic and mitogenic effects of GH.

Lipolysis mechanism: HSL and ACC

The molecular mechanism of fat metabolism modulation runs through two enzymes. Published research shows that AOD9401 (a related analogue) stimulated hormone-sensitive lipase and inhibited acetyl coenzyme A carboxylase in cultured adipocytes. HSL activation drives triglyceride breakdown for energy use; ACC inhibition reduces the conversion of acetyl-CoA into malonyl-CoA, the rate-limiting step in fatty acid synthesis. The combination of upregulating fat breakdown and downregulating fat synthesis produces the lipolytic phenotype.

Published research shows that the parent compound AOD-9401 significantly reduced lipogenic activity and increased lipolytic activity in this tissue, with AOD-9604 inheriting the same dual mechanism in its refined form. Published research shows that the functional domain responsible for the antilipogenic activity of hGH resides in the C-terminal region of the parent hormone, validating the AOD-9604 design.

Does AOD-9604 really work for weight loss?

Effect sizes are modest. Phase 2 clinical trials in obese human subjects showed weight loss of approximately 2.6 kg over 12 weeks at the most effective dose (1 mg per day), compared with 0.8 kg in the placebo group. The clinical effect size is much smaller than GLP-1 agonists (semaglutide produces 14.9 percent weight loss over 68 weeks) or tirzepatide (20.9 percent over 72 weeks). The compound failed to demonstrate sufficient efficacy for FDA approval as a weight-loss therapy, which is part of why no AOD-9604 finished pharmaceutical exists.

How much weight can you lose on AOD-9604?

Based on the available clinical data, expected weight loss over 12-24 weeks of treatment is in the 2-5 kg range, primarily from fat mass rather than lean mass. The body composition shift is favourable (fat-specific lipolysis with preserved lean mass) but the absolute weight reduction is small. For researchers studying lipolysis mechanism, the modest weight change is acceptable; for primary weight-loss endpoints, the GLP-1 class produces far larger effects.

How does AOD-9604 compare to other peptides for fat loss?

The fat-loss peptide landscape covers several mechanism classes:

• GLP-1 receptor agonists (semaglutide, liraglutide): appetite suppression, gastric emptying delay, 10-15% weight loss
• GIP/GLP-1 dual agonists (tirzepatide): same plus GIP effects, 20% weight loss at top dose
• Triple agonists (retatrutide): plus glucagon receptor activation for energy expenditure, 24% weight loss
• GHRH analogues (tesamorelin): GH-mediated visceral fat reduction, 15-18% visceral fat loss
• AOD-9604: HGH-fragment-mediated direct adipocyte lipolysis, modest 2-5 kg total weight loss
• 5-Amino-1MQ: NNMT-inhibitor cellular energy expenditure, rodent-only data

AOD-9604 occupies the smallest-effect niche but with the cleanest direct-adipocyte mechanism. It is a research tool for studying lipolysis biology, not a primary weight-loss therapy.

Dosage and administration

Published Phase 2 clinical trials used AOD-9604 at 1 mg per day by oral or subcutaneous administration. Research protocols span 300 μg to 1 mg per dose. The peptide is supplied as a lyophilised powder for reconstitution in bacteriostatic water. Oral bioavailability is documented (one of the few peptides with meaningful oral activity), though injectable routes provide more consistent pharmacokinetics in research contexts.

Side effects and safety

The safety profile is favourable. Reported adverse events in clinical and research use are minimal: occasional mild injection-site irritation, rare transient headache, and no documented hepatic, cardiac, or systemic safety signals. The peptide does not affect IGF-1 levels, glucose metabolism, or growth-related parameters, which avoids the GH-related adverse events of HGH itself. AOD-9604 was generally considered safe in the Phase 2 obesity trial program.

Who should avoid using AOD-9604?

Relative contraindications are limited but include:

• Pregnancy and breastfeeding (insufficient safety data)
• Active malignancy (precautionary, though no mitogenic signal has been documented)
• Severe hypoglycemia history (rare metabolic effect on glucose substrate selection)
• Known hypersensitivity to peptide components

Patients seeking dramatic weight loss should not expect AOD-9604 to deliver the effect sizes of GLP-1 agonists. Researchers studying lipolysis pathways are the primary appropriate use case.

When can you expect to see results?

In clinical research, body weight curves separate from placebo within 4-6 weeks of consistent dosing, with effect size building through 12-24 weeks. Body composition changes (favouring fat mass loss) are visible on DEXA scans within 8-12 weeks. Subjective effects on energy and appetite are minimal; the mechanism is silent at the perception level.

Legal status

AOD-9604 is not approved by Health Canada, the FDA, or the EMA as a finished pharmaceutical. The compound has Generally Recognised As Safe (GRAS) status in some food/dietary supplement contexts in the United States, but this status is unrelated to weight-loss medication regulation. The peptide is legal in Canada and the United States as a research chemical sold under research-use-only labelling. It is not on the World Anti-Doping Agency prohibited list.

Sourcing for research

Reproducible lipolysis research depends on the integrity of the input material:

• Batch-specific Certificate of Analysis from an independent third-party laboratory
• HPLC purity confirmation at 98 percent or above, with chromatogram trace
• Mass spectrometry verification of the expected ~1,816 Da molecular weight
• Endotoxin and sterility testing for in vivo or cell-culture work

Reviv Peptides supplies AOD-9604 with third-party COA and HPLC purity confirmation. View the AOD-9604 5mg product page.

AOD-9604 questions

Does AOD-9604 really work for weight loss?

Yes, with modest effect sizes. Phase 2 clinical data showed 2.6 kg weight loss over 12 weeks at 1 mg/day, primarily from fat mass rather than lean mass. Effect size is much smaller than GLP-1 agonists or other modern weight-loss peptides.

How much weight can you lose on AOD-9604?

Expected weight loss is in the 2-5 kg range over 12-24 weeks of treatment, primarily from fat mass. Body composition shifts favourably but absolute weight reduction is small compared with GLP-1 agonists.

Who should avoid using AOD-9604?

Pregnancy, breastfeeding, active malignancy, severe hypoglycemia history, and known peptide hypersensitivity. Patients seeking dramatic weight loss should consider GLP-1 agonists instead.

What is AOD-9604 and how does it work?

AOD-9604 is a 16-amino-acid peptide fragment of human growth hormone (residues 177-191) that mediates lipolysis without binding the hGH receptor or driving IGF-1. The mechanism is activation of hormone-sensitive lipase and inhibition of acetyl-CoA carboxylase in adipocytes.

Is AOD-9604 safe?

Safety profile is favourable. Phase 2 trials in obese subjects showed minimal adverse events, no hepatic or cardiac signals, and no IGF-1 or growth-related effects. The peptide does not produce the GH-related adverse events of full HGH administration.

Key data point: Heffernan et al. (2001, Endocrinology) showed AOD-9604 at 500 µg/kg/day in obese Zucker rats produced a 33% fat mass reduction over 19 days without affecting IGF-1 levels, lean mass, or glucose homeostasis — confirming the lipolytic effect operates through the beta-3 adrenergic receptor independently of the GH receptor, eliminating the insulin-resistance risk associated with full-length GH.

Summary

AOD-9604 is a 16-amino-acid peptide fragment of human growth hormone designed to isolate the lipolytic activity of HGH from its broader growth-promoting effects. The fragment activates hormone-sensitive lipase and inhibits acetyl-CoA carboxylase in adipocytes without binding the hGH receptor or raising IGF-1. Clinical effect on weight loss is modest (2-5 kg over 12-24 weeks), much smaller than GLP-1 agonists. The compound failed FDA approval for weight loss but has GRAS status in some food contexts. For researchers studying lipolysis biology and fat metabolism without GH-axis confounds, AOD-9604 is one of the cleanest tool peptides in the category. Legal in Canada and the United States as a research chemical under research-use-only labelling.

All products sold by Reviv Peptides are for research and educational purposes only and are not intended for human consumption. Not for diagnostic or therapeutic use of any kind. Researchers should follow institutional biosafety policies when working with research-grade peptides.